Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy
Status:
Completed
Trial end date:
2001-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
Biological therapies, such as QS21, use different ways to stimulate the immune system and
stop cancer cells from growing.
PURPOSE: Phase II trial to study the effectiveness of vaccine therapy plus QS21 in treating
patients who have small cell lung cancer that has responded to initial therapy.